7 completed, 3 recruiting, 1 not yet recruiting, 1 terminated. 14 Phase 2, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 14 | Completed 7, Recruiting 3, Not yet recruiting 1, Terminated 1, Unknown 1, Withdrawn 1 |
| Phase 3 | 3 | Completed 2, Recruiting 1 |
Follow Mental Disorder: new trials by email Literature Review of Mental Disorder trials Research Report on Mental Disorder
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Virtual Menstrual Pain Approaches in Females Virtual Auricular Acupressure, Virtual Baduanjin Qigong Exercise, Self Education - Pain (Visceral, Somatic, or Neuropathic), Women of Reproductive Age | Phase 2 / Phase 3 | Recruiting | Nanyang Technological University | 145 | 2026-04-15 | 2026-06-23 |
| Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness Transcranial magnetic stimulation - Major Depressive Disorder, Obsessive-Compulsive Disorder | Phase 2 | Recruiting | Brigham and Women's Hospital | 180 | 2025-01-30 | 2026-07-16 |
| GLP-1R Agonist Treatment for Opioid Use Disorder Semaglutide Pen Injector, Placebo - Opioid Use Disorder, Opioid Abuse and Addiction | Phase 2 | Recruiting | Milton S. Hershey Medical Center | 200 | 2025-01-27 | 2026-08-28 |
| Connectomic Targeted TMS Target for Refractory Anxiety Transcranial magnetic stimulation, Sham transcranial magnetic stimulation - Anxiety Disorders, Mental Disorder | Phase 2 | Not yet recruiting | Brigham and Women's Hospital | 80 | 2024-08-01 | 2024-04-19 |
| Individualized Functional Connectivity Targeting in aiTBS for Depression transcranial magnetic stimulation - Depressive Disorder, Major, Depression | Phase 2 | Completed | Brigham and Women's Hospital | 40 | 2023-07-15 | 2026-08-25 |
| Psilocybin for the Treatment of Veterans With Post-Traumatic Stress Disorder Psilocybin - PTSD, Stress Disorders, Traumatic | Phase 2 | Completed | Ohio State University | 12 | 2023-01-01 | 2026-10-16 |
| A Clinical Trial of PRAX-114 in Participants With Post-Traumatic Stress Disorder 60 mg PRAX-114 or 40 mg PRAX-114, Placebo, 40 mg PRAX-114 - Post-traumatic Stress Disorder, Post Traumatic Stress Disorder | Phase 2 | Terminated | Praxis Precision Medicines | 11 | 2022-01-25 | 2022-12-01 |
| High Dose Omega 3 in People at Risk for Dementia Omega-3 capsules, Olive oil - Dementia, Inflammation | Phase 2 | Unknown | University Hospital, Akershus | 40 | 2018-10-01 | 2019-04-24 |
| A Clinical Trial of Oral Ganaxolone in Women With Postpartum Depression Ganaxolone, Placebo - Depressive Disorder, Depression | Phase 2 | Completed | Marinus Pharmaceuticals | 84 | 2017-12-28 | 2023-08-18 |
| Open-label Study to Assess Usability of the Medical Information Device #1 (MIND1) System in Adults With Schizophrenia On Oral Aripiprazole MIND1 System - Schizophrenia, Mental Disorder | Phase 2 | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | 67 | 2014-08-01 | 2018-08-15 |
| Adherence to Treatment, Safety and Tolerability Study of the Medical Information Device #1 (MIND1) in Subjects With Schizophrenia or Bipolar I Disorder Aripiprazole, Ingestible Event Marker (IEM) - Bipolar 1 Disorder, Schizophrenia | Phase 2 | Withdrawn | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2014-03-01 | 2015-04-28 | |
| Engaging Homeless Youth in Vocational Training to Meet Their Mental Health Needs Social Enterprise Intervention, IPS - Mental Disorder, Mental Health | Phase 2 | Completed | Arizona State University | 72 | 2009-09-18 | 2017-04-18 |
| Homeopathic Medication and Nutritional Oriented Diet to Treat Overweight Pregnant Women With Mental Disorder Sulph, Puls, Lyc, Lack t, Con, Sep, Nux v, Calc c, Phos, Homeopathy and Nutritional oriented diet - Overweight, Pregnancy | Phase 2 / Phase 3 | Completed | Edgard Costa de Vilhena | 134 | 2009-08-01 | 2013-05-13 |
| 15 Year Follow-up of New Beginnings Program for Divorced Families New Beginnings Program - Mental Disorder, Substance Use | Phase 2 / Phase 3 | Completed | Arizona State University | 240 | 2006-07-01 | 2011-08-02 |
Mental Disorders (14) · Depression (3) · Mood Disorders (3) · Nervous System Diseases (3) · Schizophrenia (3) · Anxiety Disorders (2) · Depressive Disorder, Major (2) · Stress Disorders, Post-Traumatic (2) · Stress Disorders, Traumatic (2) · Substance-Related Disorders (2) · Trauma and Stressor Related Disorders (2) · Treatment Adherence and Compliance (2) · Behavior, Addictive (1) · Behavioral Symptoms (1) · Brain Diseases (1)
Behavior (7) · Pathological Conditions, Signs and Symptoms (3) · Schizophrenia Spectrum and Other Psychotic Disorders (3) · Behavioral Symptoms (2) · Depressive Disorder (2) · Health Behavior (2) · Signs and Symptoms (2) · Body Weight (1) · Chemically-Induced Disorders (1) · Compulsive Behavior (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Impulsive Behavior (1) · Neurologic Manifestations (1) · Nutrition Disorders (1) · Nutritional and Metabolic Diseases (1)
Transcranial Magnetic Stimulation (3) · Aripiprazole (1) · Docosahexaenoic Acids (1) · Employment, Supported (1) · Homeopathy (1) · Olive Oil (1) · Palliative Care (1) · Phosphorus (1) · Phosphorus, Dietary (1) · Psilocybin (1) · Selenoprotein P (1) · Sulfur (1) · ganaxolone (1) · semaglutide (1)
Brigham and Women's Hospital (3) · Arizona State University (2) · Otsuka Pharmaceutical Development & Commercialization, Inc. (2) · Edgard Costa de Vilhena (1) · Marinus Pharmaceuticals (1) · Milton S. Hershey Medical Center (1) · Nanyang Technological University (1) · Ohio State University (1) · Praxis Precision Medicines (1) · University Hospital, Akershus (1)
United States (10) · Brazil (1) · Norway (1) · Singapore (1)
Alan K Davis, PhD (1) · Edgard C Vilhena, MD (1) · Jennifer Nyland, PhD (1) · Joseph Hulihan, MD (1) · Joseph J Taylor, MD, PhD (1) · Shan H Siddiqi, MD (1) · Shan Siddiqi, MD (1) · Sharlene A Wolchik, Ph.D. (1) · Shashank Rohatagi, PhD (1) · Timothy Peters-Strickland, MD (1) · Tormod Fladby, MD PhD (1)
PMID 23750466, PMID 24484456, PMID 25367835, PMID 25382415, PMID 26465217, PMID 26692236, PMID 37142308, PMID 38085556, PMID 40502777, PMID 41168808, PMID 42340706, PMID 42533157
P30MH068685 (1), UH3DA050325 (1)